Chargement en cours...
Dose comparison of conivaptan (Vaprisol(®)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics
PURPOSE: This study aimed to evaluate the efficacy, safety, and pharmacokinetics of 20 and 40 mg/day conivaptan (Vaprisol(®)) in patients with hypervolemic or euvolemic hyponatremia. METHODS: Hyponatremic patients – serum sodium (sNa) ≤130 mEq/L – received either 20 or 40 mg/day of conivaptan for 4...
Enregistré dans:
| Publié dans: | Drug Des Devel Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4723016/ https://ncbi.nlm.nih.gov/pubmed/26848258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S95326 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|